Adoptive T-cell therapy for cancer: the era of engineered T cells
Open accessThe DOI matches its Crossref record; 133 of the 134 references it cites were found in a registry or an index.
Abstract
Tumors originate from a number of genetic events that deregulate homeostatic mechanisms controlling normal cell behavior. The immune system, devoted to patrol the organism against pathogenic events, can identify transformed cells, and in several cases cause their elimination. It is however clear that several mechanisms encompassing both central and peripheral tolerance limit antitumor immunity, often resulting into progressive diseases. Adoptive T-cell therapy with either allogeneic or autologous T cells can transfer therapeutic immunity. To date, genetic engineering of T cells appears to be a powerful tool for shaping tumor immunity. In this review, we discuss the most recent achievements in the areas of suicide gene therapy, and TCR-modified T cells and chimeric antigen receptor gene-modified T cells. We provide an overview of current strategies aimed at improving the safety and efficacy of these approaches, with an outlook on prospective developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TCR-engineered T cells or CAR-engineered T cells increase the efficacy of the antitumor immune response (79).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,179
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,161
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 814
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
Xu, Y., Zhang, M., Ramos, C. A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C. J., Gee, A. P., Heslop, H. E., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552174 · Cited by 744
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Cameron, B. J., Gerry, A. B., Dukes, J., Harper, J. V., Kannan, V., Bianchi, F. C., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 684
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 625
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Molecular regulation of effector and memory T cell differentiation
Chang, J. T., Wherry, E. J., & Goldrath, A. W. (2014) · Nature Immunology · doi:10.1038/ni.3031 · Cited by 582
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70074-9 · Cited by 488
The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism
Powell, J. D., & Delgoffe, G. M. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.002 · Cited by 486
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A. D. M., Pouw, N., Debets, R., Kieback, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2128 · Cited by 448
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448
Self-citationRosenberg, S. A., Sportès, C., Ahmadzadeh, M., Fry, T. J., Ngo, L. T., Schwarz, S. L., Stetler-Stevenson, M., Morton, K. E., Mavroukakis, S. A., Morre, M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000210386.55951.c2 · Cited by 443
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378
Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 357
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
Crompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R. L., Tran, E., Hanada, K.-I., Yu, Z., Palmer, D. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2277 · Cited by 345
Berger, C., Flowers, M. E., Warren, E. H., & Riddell, S. R. (2006) · Blood · doi:10.1182/blood-2005-08-3503 · Cited by 334
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Heczey, A., Liu, D., Tian, G., Courtney, A. N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-541235 · Cited by 318
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., Garcia, M. R., Sherry, R. M., Yang, J. C., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 315
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312
T cell metabolic fitness in antitumor immunity
Siska, P. J., & Rathmell, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.007 · Cited by 312
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K. D., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 311
Superior T memory stem cell persistence supports long-lived T cell memory
Lugli, E., Dominguez, M. H., Gattinoni, L., Chattopadhyay, P. K., Bolton, D. L., Song, K., Klatt, N. R., Brenchley, J. M., Vaccari, M., Gostick, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66327 · Cited by 302
Ciceri, F., Labopin, M., Aversa, F., Rowe, J. M., Bunjes, D., Lewalle, P., Nagler, A., Di Bartolomeo, P., Lacerda, J. F., Lupo Stanghellini, M. T., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140095 · Cited by 279
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31827806e6 · Cited by 277
Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine
Smee, D. F., Martin, J. C., Verheyden, J. P., & Matthews, T. R. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.5.676 · Cited by 265
Chodon, T., Comin-Anduix, B., Chmielowski, B., Koya, R. C., Wu, Z., Auerbach, M., Ng, C., Avramis, E., Seja, E., Villanueva, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3017 · Cited by 259
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239
Mixed T cell receptor dimers harbor potentially harmful neoreactivity
van Loenen, M. M., de Boer, R., Amir, A. L., Hagedoorn, R. S., Volbeda, G. L., Willemze, R., van Rood, J. J., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005802107 · Cited by 232
Feldkamp, M. M., Feldkamp, M. M., Lala, P., Lau, N., Roncari, L., Guha, A., Guha, A., & Guha, A. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00034 · Cited by 227
Database of T cell-defined human tumor antigens: the 2013 update.
Vigneron, N., Stroobant, V., den Eynde, B. J. V., & van der Bruggen, P. (2013) · Europe PMC (PubMed Central) · Cited by 226
Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W. W., Lizée, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0712 · Cited by 222
Zhou, X., Dotti, G., Krance, R. A., Martinez, C. A., Naik, S., Kamble, R. T., Durett, A. G., Dakhova, O., Savoldo, B., Di Stasi, A., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628354 · Cited by 216
Storb, R., Gyurkocza, B., Storer, B. E., Sorror, M. L., Blume, K., Niederwieser, D., Chauncey, T. R., Pulsipher, M. A., Petersen, F. B., Sahebi, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0247 · Cited by 214
Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor
Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177092b · Cited by 210
Traversari, C., Marktel, S., Magnani, Z., Mangia, P., Russo, V., Ciceri, F., Bonini, C., & Bordignon, C. (2007) · Blood · doi:10.1182/blood-2006-04-015230 · Cited by 206
Designing chimeric antigen receptors to effectively and safely target tumors
Jensen, M. C., & Riddell, S. R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.002 · Cited by 204
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Bonini, C., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.312 · Cited by 201
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F., & Di Stasi, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 201
Okamoto, S., Mineno, J., Ikeda, H., Fujiwara, H., Yasukawa, M., Shiku, H., & Kato, I. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1450 · Cited by 186
Deniger, D. C., Switzer, K., Mi, T., Maiti, S., Hurton, L., Singh, H., Huls, H., Olivares, S., Lee, D. A., Champlin, R. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.267 · Cited by 184
High-throughput identification of antigen-specific TCRs by TCR gene capture
Linnemann, C., Heemskerk, B., Kvistborg, P., Kluin, R. J. C., Bolotin, D. A., Chen, X., Bresser, K., Nieuwland, M., Schotte, R., Michels, S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3359 · Cited by 177
Biasco, L., Scala, S., Basso Ricci, L., Dionisio, F., Baricordi, C., Calabria, A., Giannelli, S., Cieri, N., Barzaghi, F., Pajno, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010314 · Cited by 175
Self-citationSafety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 173
Zhou, X., Di Stasi, A., Tey, S.-K., Krance, R. A., Martinez, C., Leung, K. S., Durett, A. G., Wu, M.-F., Liu, H., Leen, A. M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-551671 · Cited by 172
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy
Johansson, A., Hamzah, J., Payne, C. J., & Ganss, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118296109 · Cited by 172
Chinnasamy, N., Wargo, J. A., Yu, Z., Rao, M., Frankel, T. L., Riley, J. P., Hong, J. J., Parkhurst, M. R., Feldman, S. A., Schrump, D. S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001775 · Cited by 161
Kaneko, S., Mastaglio, S., Bondanza, A., Ponzoni, M., Sanvito, F., Aldrighetti, L., Radrizzani, M., La Seta-Catamancio, S., Provasi, E., Mondino, A., et al. (2009) · Blood · doi:10.1182/blood-2008-05-156059 · Cited by 157
Pegram, H. J., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Giralt, S. A., Barker, J. N., & Brentjens, R. J. (2015) · Leukemia · doi:10.1038/leu.2014.215 · Cited by 155
Gras, S. L., Günthert, U., Stauder, R., Curt, F., Oliferenko, S., Kluin‐Nelemans, H. C., Marie, J., Proctor, S., Jasmin, C., & Smadja‐Joffe, F. (1998) · Blood · doi:10.1182/blood.v91.9.3401 · Cited by 154
Crucitti, L., Crocchiolo, R., Toffalori, C., Mazzi, B. A., Greco, R., Signori, A., Sizzano, F., Chiesa, L., Zino, E., Stanghellini, M. T. L., et al. (2014) · Leukemia · doi:10.1038/leu.2014.314 · Cited by 148
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
Reissfelder, C., Stamova, S., Gossmann, C., Braun, M., Bonertz, A., Walliczek, U., Grimm, M., Rahbari, N. N., Koch, M., Saadati, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74894 · Cited by 142
Calcinotto, A., Grioni, M., Jachetti, E., Curnis, F., Mondino, A., Parmiani, G., Corti, A., & Bellone, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101877 · Cited by 140
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Griffioen, M., van Egmond, E. H. M., Kester, M. G. D., Willemze, R., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2009) · Haematologica · doi:10.3324/haematol.2008.001677 · Cited by 137
Cieri, N., Oliveira, G., Greco, R., Forcato, M., Taccioli, C., Cianciotti, B., Valtolina, V., Noviello, M., Vago, L., Bondanza, A., et al. (2015) · Blood · doi:10.1182/blood-2014-11-608539 · Cited by 134
Engineered T cells for cancer therapy
June, C. H., Maus, M. V., Plesa, G., Johnson, L. A., Zhao, Y., Levine, B. L., Grupp, S. A., & Porter, D. L. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1568-1 · Cited by 124
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
Duong, C. P. M., Yong, C. S. M., Kershaw, M. H., Slaney, C. Y., & Darcy, P. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.12.009 · Cited by 123
SHP-1 phosphatase activity counteracts increased T cell receptor affinity
Hebeisen, M., Baitsch, L., Presotto, D., Baumgaertner, P., Romero, P., Michielin, O., Speiser, D. E., & Rufer, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65325 · Cited by 123
Ochi, T., Fujiwara, H., Okamoto, S., An, J., Nagai, K., Shirakata, T., Mineno, J., Kuzushima, K., Shiku, H., & Yasukawa, M. (2011) · Blood · doi:10.1182/blood-2011-02-337089 · Cited by 121
Obenaus, M., Leitão, C., Leisegang, M., Chen, X. T., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D. J., & Blankenstein, T. J. F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3147 · Cited by 120
Optogenetic control of chemokine receptor signal and T-cell migration
Xu, Y., Hyun, Y., Lim, K., Lee, H., Cummings, R. J., Gerber, S. A., Bae, S., Cho, T. Y., Lord, E. M., & Kim, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319296111 · Cited by 118
Improving the safety of cell therapy with the TK-suicide gene
Greco, R., Oliveira, G., Stanghellini, M. T. L., Vago, L., Bondanza, A., Peccatori, J., Cieri, N., Marktel, S., Mastaglio, S., Bordignon, C., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00095 · Cited by 116
van der Waart, A. B., van de Weem, N. M. P., Maas, F., Kramer, C. S. M., Kester, M. G. D., Falkenburg, J. H. F., Schaap, N., Jansen, J. H., van der Voort, R., Gattinoni, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578583 · Cited by 116
Ohno, M., Ohkuri, T., Kosaka, A., Tanahashi, K., June, C. H., Natsume, A., & Okada, H. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-21 · Cited by 108
A novel self-lipid antigen targets human T cells against CD1c+ leukemias
Lepore, M., de Lalla, C., Gundimeda, S. R., Gsellinger, H., Consonni, M., Garavaglia, C., Sansano, S., Piccolo, F., Scelfo, A., Häussinger, D., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140410 · Cited by 97
Hematopoietic stem cells for cancer immunotherapy
Gschweng, E., De Oliveira, S., & Kohn, D. B. (2014) · Immunological Reviews · doi:10.1111/imr.12128 · Cited by 89
Targeting cancer-specific mutations by T cell receptor gene therapy
Blankenstein, T., Leisegang, M., Uckert, W., & Schreiber, H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.005 · Cited by 88
Stromnes, I. M., Blattman, J. N., Tan, X., Jeevanjee, S., Gu, H., & Greenberg, P. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41991 · Cited by 85
Re‐adapting T cells for cancer therapy: from mouse models to clinical trials
Stromnes, I. M., Schmitt, T. M., Chapuis, A. G., Hingorani, S. R., & Greenberg, P. D. (2014) · Immunological Reviews · doi:10.1111/imr.12141 · Cited by 82
Party, O. B. O. T. E. S. T. W., Demirer, T., Barkholt, L., Blaise, D., Pedrazzoli, P., Aglietta, M., Carella, A. M., Bay, J., Arpacı, F., Rosti, G., et al. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1104 · Cited by 81
Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma
Baldan, V, Griffiths, R., Hawkins, R. E., & Gilham, D. E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.96 · Cited by 80
Gansauge, F., Gansauge, S., Zobywalski, A., Scharnweber, C., Link, K. H., Nussler, A. K., & Beger, H. G. (1995) · PubMed · Cited by 72
Survivin-specific T cell receptor targets tumor but not T cells
Arber, C., Feng, X., Abhyankar, H. A., Romero, E., Wu, M., Heslop, H. E., Barth, P., Dotti, G., & Savoldo, B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75876 · Cited by 72
Bunse, M., Bendle, G. M., Linnemann, C., Bies, L., Schulz, S., Schumacher, T. N., & Uckert, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.142 · Cited by 67
Liebisch, P., Eppinger, S., Schöpflin, C., Stehle, G., Munzert, G. M., Döhner, H., & Schmid, M. (2005) · PubMed · Cited by 64
TCR repertoires of intratumoral T‐cell subsets
Linnemann, C., Mezzadra, R., & Schumacher, T. N. M. (2014) · Immunological Reviews · doi:10.1111/imr.12140 · Cited by 63
Schmitt, T. M., Aggen, D. H., Stromnes, I. M., Dossett, M. L., Richman, S. A., Kranz, D. M., & Greenberg, P. D. (2013) · Blood · doi:10.1182/blood-2013-01-478164 · Cited by 62
Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges
Dhodapkar, M. V., & Richter, J. R. (2011) · Clinical Immunology · doi:10.1016/j.clim.2010.12.010 · Cited by 61
Chimeric Antigen Receptor T Cells for Cancer Immunotherapy
Curran, K. J., & Brentjens, R. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3449 · Cited by 60
Hinterleitner, R., Gruber, T., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Tzankov, A., Schuster, M., Penninger, J. M., Loibner, H., Lametschwandtner, G., Wolf, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044295 · Cited by 59
Vago, L., Oliveira, G., Bondanza, A., Noviello, M., Soldati, C., Ghio, D., Brigida, I., Greco, R., Stanghellini, M. T. L., Peccatori, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405670 · Cited by 58
Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation
Cieri, N., Mastaglio, S., Oliveira, G., Casucci, M., Bondanza, A., & Bonini, C. (2013) · Immunological Reviews · doi:10.1111/imr.12130 · Cited by 57
Dössinger, G., Bunse, M., Bet, J., Albrecht, J., Paszkiewicz, P. J., Weißbrich, B., Schiedewitz, I., Henkel, L., Schiemann, M., Neuenhahn, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061384 · Cited by 54
Svane, I. M., & Verdegaal, E. M. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1580-5 · Cited by 53
Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer
Bendle, G. M., Linnemann, C., Bies, L., Song, J.-Y., & Schumacher, T. N. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301270 · Cited by 43
Bondanza, A., Hambach, L., Aghai, Z., Nijmeijer, B., Kaneko, S., Mastaglio, S., Radrizzani, M., Fleischhauer, K., Ciceri, F., Bordignon, C., et al. (2011) · Blood · doi:10.1182/blood-2010-11-320366 · Cited by 41
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer
Bellone, M., Mondino, A., & Corti, A. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.003 · Cited by 37
Experts’ considerations on HLA ‐haploidentical stem cell transplantation
Patriarca, F. F., Luznik, L., Medeot, M., Zecca, M., Bacigalupo, A. P., Bartolomeo, P. D., Arcese, W., Corradini, P., Ciceri, F., Vago, L., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12322 · Cited by 34
Use of TK-cells in haploidentical hematopoietic stem cell transplantation
Oliveira, G., Greco, R., Stanghellini, M. T. L., Vago, L., & Bonini, C. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835822f5 · Cited by 33
Michelini, R. H., Freschi, M., Manzo, T., Jachetti, E., Degl'Innocenti, E., Grioni, M., Basso, V., Bonini, C., Simpson, E., Mondino, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4253 · Cited by 26
Posttransplantation Vaccination: Concepts Today and on the Horizon
Rezvani, K. (2011) · Hematology · doi:10.1182/asheducation-2011.1.299 · Cited by 26
Won’t you come on in? How to favor lymphocyte infiltration in tumors
Bellone, M., Calcinotto, A., & Corti, A. (2012) · OncoImmunology · doi:10.4161/onci.20213 · Cited by 23
Michelini, R. H., Manzo, T., Sturmheit, T., Basso, V., Rocchi, M., Freschi, M., Listopad, J. J., Blankenstein, T. J. F., Bellone, M., & Mondino, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3464 · Cited by 19
Reuß, S., Sebestyén, Z., Heinz, N., Loew, R., Baum, C., Debets, R., & Uckert, W. (2013) · European Journal of Immunology · doi:10.1002/eji.201343591 · Cited by 16
Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation
Filatenkov, A., Müller, A. M. S., Tseng, W. W., Dejbakhsh‐Jones, S., Winer, D. A., Luong, R. H., Shizuru, J. A., Engleman, E. G., & Strober, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900159 · Cited by 12
Genetic Modification of Cytotoxic T Lymphocytes to Express Cytokine Receptors
Perna, S. K., Savoldo, B., & Dotti, G. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0345-0_17 · Cited by 4
Research works printed but not linked: 3
- C 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu 15214141, 2015, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/eji.201545552, Wiley Online Library on [09/08/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
- C 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu 15214141, 2015, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/eji.201545552, Wiley Online Library on [09/08/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License Eur. J. Immunol. 2015. 45: 2457-2469 REVIEWS 2469 119
- Milan, Italy e-mail: chiara.bonini@hsr.it See all the ECI 2015 Reviews at http://onlinelibrary.wiley.com/journal/ 10.1002/(ISSN)1521-4141/homepage/eci2015.htm · doi:10.1002/(issn)1521-4141/homepage/eci2015.htm
Cited by
Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., de la Cámara, R., Corbacioglu, S., Dolstra, H., Duarte, R., Glass, B., Greco, R., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01227-8 · Cited by 429
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Bonini, C., Duarte, R. F., Dufour, C., Gennery, A., Kröger, N., Kuball, J., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.34 · Cited by 395
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., & Wu, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.03.001 · Cited by 246
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., Corbacioglu, S., Duarte, R., Dolstra, H., Lankester, A. C., Mohty, M., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0826-4 · Cited by 187
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0465-9 · Cited by 173
Metadata
- Authors
- Bonini, C., & Mondino, A.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- Corresponding author
- Bonini, Chiara
- Mondino, Anna
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2015-08-21
- Volume
- 45
- Issue
- 9
- Pages
- 2457-2469
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1957268835
- Cited by
- 93
- References
- 134
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 10 · 2022: 10 · 2021: 10 · 2020: 8 · 2019: 16 · 2018: 12 · 2017: 8 · 2016: 7
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG 11970 and IG 15883)
- Fifth Framework Programme (LSHC-CT-2005-018914 ATTACK)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- adoptive T cell therapy, engineered T cells, suicide gene therapy, chimeric antigen receptor T cells, antitumor immunity, tumor immune evasion, allogeneic T cells, autologous T cells
- MeSH terms
- Antigens, Neoplasm, Forecasting, Humans, Neoplasms, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Gene Expression, Immunotherapy, Adoptive, Genes, Transgenic, Suicide, Mutant Chimeric Proteins, Cell Engineering, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.